iOrganBio Taps Karol Jarzabek as Chief Operating Officer

iOrganBio, an innovator in intelligent cell manufacturing, has appointed Karol Jarzabek as Chief Operating Officer.

A seasoned operations leader with deep expertise in driving strategic value and operational excellence across complex environments, including the biopharmaceutical sector, Jarzabek will lead and scale iOrganBio’s operations, manufacturing, and supply chain functions as the company advances CellForge, its closed-loop platform for precise human cell production.

“We are advancing our infrastructure to enable predictable, reproducible and scalable manufacturing of human cells,” said Daniel Delubac, co-founder and CEO of iOrganBio. “Karol brings extensive experience designing operational structures and aligning teams across life science businesses, with a proven track record of translating strategy into measurable results.”

Experience

Jarzabek brings broad expertise in operational management and business transformation, supported by advanced training in predictive analytics and experience deploying AI-enabled systems across global organizations.

Most recently, he served as Vice President of Portfolio Operations at QHP Capital, where he led value creation initiatives across 13 life science and pharmaceutical services companies, spanning partnership development and end-to-end value chain execution. Prior to QHP Capital, Jarzabek held multiple senior leadership roles at Azurity Pharmaceuticals, including Vice President of Strategic Finance and President of Established Brands, where he led M&A execution, operational integration and portfolio management efforts.

“What impressed me about iOrganBio is how intentionally the platform was designed from the start. There is strong integration between the science and data infrastructure,” said Jarzabek. “The team is applying true engineering rigor to complex biological systems, creating a foundation that can actually scale. This approach has the potential to fundamentally change how therapies are developed for patients, and I am excited to help translate that vision into durable, scalable operations as the company grows.”